Shares of Telix Pharmaceuticals (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.

The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.

The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.

The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.